Caring for COVID-19 patients on PN
As an alternative ILE with four oil sources, SMOFlipid aligns with the most current SCCM/ASPEN guidance for COVID-19 patients requiring ICU care, which recommends limiting the use of pure soybean oil ILEs.4
Supply of monounsaturated fatty acids
Mix of fatty acids may have less pro-inflammatory properties1
Omega-3 fatty acids from fish oil include EPA and DHA
First and only 4-oil lipid emulsion
SMOFlipid is the FIRST and ONLY 4-oil lipid injectable emulsion with demonstrated safety and tolerability2,3 in more than 6 million patients worldwide.*
Limitations of Use:
The omega-6: omega-3 fatty acid ratio and Medium Chain Triglycerides in SMOFlipid have not been shown to improve clinical outcomes compared to other intravenous lipid emulsions.
Important safety information> Full prescribing information>
*Data on file.
As an alternative ILE with four oil sources, SMOFlipid aligns with the most current SCCM/ASPEN guidance for COVID-19 patients requiring ICU care, which recommends limiting the use of pure soybean oil ILEs.4
Each oil has a special characteristic which provides a unique blend. Clinical studies have shown several benefits of the blend:
SMOFlipid showed lower concentrations of liver enzymes (ALT, AST) compared to soybean oil lipid emulsions, indicating an improvement in the patient’s liver function.2,6
Monitor liver function. If SMOFlipid-treated patients develop liver test abnormalities, consider discontinuation or dose reduction.
Triglyceride levels increased less with SMOFlipid compared to lipid emulsions with higher soybean oil content.5,6
Company-sponsored studies showed that mean triglyceride levels from baseline values to week 4 were similar in both the SMOFlipid and comparator groups.
Indication:
SMOFlipid is indicated in adults as a source of calories and essential fatty acids for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated.
Limitations of Use:
The omega-6:omega-3 fatty acid ratio and Medium Chain Triglycerides in SMOFlipid have not been shown to improve clinical outcomes compared to other intravenous lipid emulsions.
Fresenius Kabi offers an industry standard patient support program, KabiCare. Claims appeals and billing and coding support resources for Parenteral Nutrition are available for your eligible patients.
Explore additional SMOFlipid materials by visiting our Resource Center.
SMOFLIPID (lipid injectable emulsion), for intravenous use
BRIEF SUMMARY OF PRESCRIBING INFORMATION
This brief summary does not include all the information needed to use SMOFlipid safely and effectively. Please see full prescribing information, including Boxed Warning for SMOFlipid (lipid injectable emulsion), for intravenous use at www.freseniuskabinutrition.com.
WARNING: DEATH IN PRETERM INFANTS
INDICATIONS AND USAGE
SMOFlipid is indicated in adults as a source of calories and essential fatty acids for parenteral nutrition (PN) when oral or enteral nutrition is not possible, insufficient, or contraindicated.
Limitations of Use:
The omega-6: omega-3 fatty acid ratio and Medium Chain Triglycerides in SMOFlipid have not been shown to improve clinical outcomes compared to other intravenous lipid emulsions.
SMOFLIPID (lipid injectable emulsion), for intravenous use
BRIEF SUMMARY OF PRESCRIBING INFORMATION
This brief summary does not include all the information needed to use SMOFlipid safely and effectively. Please see full prescribing information, including Boxed Warning for SMOFlipid (lipid injectable emulsion), for intravenous use at www.freseniuskabinutrition.com.
WARNING: DEATH IN PRETERM INFANTS
INDICATIONS AND USAGE
SMOFlipid is indicated in adults as a source of calories and essential fatty acids for parenteral nutrition (PN) when oral or enteral nutrition is not possible, insufficient, or contraindicated.
Limitations of Use:
The omega-6: omega-3 fatty acid ratio and Medium Chain Triglycerides in SMOFlipid have not been shown to improve clinical outcomes compared to other intravenous lipid emulsions.
References: 1. Vanek VW, et al. A.S.P.E.N. position paper: Clinical role for alternative intravenous fat emulsions. Nutr Clin Pract. 2012;27(2):150-192. 2. Klek S, et al. Four-week parenteral nutrition using a third-generation lipid emulsion (SMOFlipid): a double-blind, randomised, multicentre study in adults. Clin Nutr. 2013;32(2):224-231. 3. Mertes N, et al. Safety and efficacy of a new parenteral lipid emulsion (SMOFlipid) in surgical patients: a randomized, double-blind, multicenter study. Ann Nutr Metab. 2006;50(3):253-259. 4. Martindale R, Patel JJ, Taylor B, Warren M, McClave SA. Nutrition therapy in the patient with COVID-19 disease requiring ICU care. Joint Recommendations from SCCM and ASPEN. Published online at https://www.sccm.org/COVID19RapidResources/Resources/Nutrition-Therapy-in-the-Patient-with-COVID-19-Dis. Updated April 1, 2020. Accessed January 11, 2022. 5. Donoghue V. Schleicer GK Spruyt MGL., et al. Four-oil lipid intravenous lipid emulsion effect on plasma fatty acid composition, inflammatory markers and clinical outcomes in acutely ill patients: A randomized control trial (Foil fact) Clin Nutr. 2018 doi:10.1016/jclnu.2018.12.010. (Epub ahead of print) 6. Antébi H, et al. Liver function and plasma antioxidant status in intensive care unit patients requiring total parenteral nutrition: comparison of 2 fat emulsions. JPEN J Parenter Enteral Nutr. 2004;28(3):142-148. 7. Deckelbaum RJ, et al. Medium-chain versus long-chain triacylglycerol emulsion hydrolysis by lipoprotein lipase and hepatic lipase: implications for the mechanisms of lipase action. Biochemistry (Mosc). 1990;29(5):1136-1142. 8. Kalish BT, Fallon EM, Puder M. JPEN J Parenter Enteral Nutr. 2012;36:380-8.